Type1 Diabetes Mellitus
66
4
6
40
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
14 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.1%
4 terminated out of 66 trials
90.9%
+4.4% vs benchmark
5%
3 trials in Phase 3/4
35%
14 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (66)
Ixekizumab Diabetes Intervention Trial (I-DIT)
Genetics Of Autoimmunity In Type I Diabetes
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
Glucagon-like Peptide-1 in Type 1 Diabetes
Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
Mechanisms for Restoration of Hypoglycemia Awareness
China Diabetes Registry by Metabolic Management Center
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus
"POWER2DM Evaluation Campaign"
Dapagliflozin Effects on Hypoglycemia
Comparison of Motor and Sensory Functions of the Hand in Children With Type 1 Diabetes Mellitus and Their Healthy Peers
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
Comparison of Real-time CGMS With Intermittently-scanned CGMS in Adolescents and Adults With Type 1 Diabetes Mellitus
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus